Company intelligence / Profile preview

Kingdom Story

United Kingdom

Ownership: Private
Development stage: Other

Overview

Kingdom Therapeutics completed a positive pre-IND meeting with FDA for KT-20610. The company has presented key pre-clinical results at major US autism conferences. Clinical trials are being facilitated by 5 Horizons Capital with Novotech selected as CRO.

Therapeutic areas: GastroenterologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

Novotech (CRO partnership)5 Horizons Capital

Beyond the preview

Go deeper on Kingdom Story.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kingdom Story.

Explore the full profile